Double-Blind, Randomized, Placebo and Alprazolam-Controlled Three-Period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-Like fMRI Activity of GW876008 and GSK561679 After Single-Dose Administration in Subjects With Social Anxiety Disorder (SAD).
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Emicerfont (Primary) ; Verucerfont (Primary) ; Alprazolam
- Indications Social phobia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 29 Oct 2012 Additional information source identified and integrated European Clinical Trials database record EudraCT2006-004212-48
- 15 Oct 2008 Actual start date changed from Feb 2007 to Mar 2007 as reported by Clinicaltrials.gov.